Pathos AI Partners with AstraZeneca to Advance AZD4241 for ER+ Breast Cancer
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
LILLE & PARIS, France, Aug. 4, 2026 4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase...
SAN DIEGO, California, July 2, 2026 Circular Genomics has unveiled CircPATHâ„¢, its proprietary circular RNA (circRNA) discovery and validation...
ROSEMONT, Illinois, July 2, 2026 The American Academy of Orthopaedic Surgeons (AAOS) has released its first-ever Clinical Practice Guideline...
SANDWICH, UK, June 3, 2026 Levicept Ltd announced new data from its Phase 2 clinical trial of LEVI-04, a...
PRINCETON, N.J., June 1, 2026 Made Scientific has been selected as the manufacturing partner for Columbia University’s NOVAKnee program,...
Boulder, Colorado, USA, April 6, 2026 $33.5M ARPA-H Funding Accelerates Regenerative Pipeline In a major boost to regenerative medicine...
Nes-Ziona, Israel — Nov. 24, 2025 — Enlivex Therapeutics Ltd. announced positive six-month topline results from the Phase IIa...
